Navigation Links
Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
Date:11/21/2013

is.  This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  The APPY1 Test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  While FDA clearance is being sought, an initial launch for the APPY1 Test is ongoing in select European countries.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1 Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively m
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
2. Venaxis Announces Pricing of Offering of Common Stock and Warrants
3. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
4. Dyadic International To Present At Two Major Conferences In December 2013
5. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
9. Accuray to Present at Piper Jaffray 25th Annual Healthcare Conference
10. Cartes 2013: DERMALOG Presents World Firsts in Biometrics
11. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... N.J. , July 22, 2014 The Board ... BDX ) has declared a quarterly dividend of 54.5 ... holders of record on September 9, 2014. The indicated annual ... About BD BD is a leading medical technology company ... the world,s most pressing and evolving health needs. Our innovative ...
(Date:7/22/2014)... Baughn, a senior lecturer in mechanical engineering at the ... of the Year by the North Texas section of ... has more than 130,000 members in 158 countries who ... to assist the engineering community, benefiting the world. , ... Society of Professional Engineers honors banquet. Baughn retired as ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Automated cell ... and maintenance of cell culture. They allow production of ... needs of researchers in drug discovery and industries and ... in mAb production, iPSC research, cryobanking, cell-based assays, and ... contamination risk. , Analysts forecast the Global Cell ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 OHAUS ... portable, and mechanical balances and scales, proudly announces ... has won Laboratory Equipment magazine’s 2014 “Readers' Choice” ... second consecutive year the Explorer was voted the ... annual Readers’ Choice Awards celebrates “excellence in product ...
Breaking Biology Technology:UT Dallas professor receives Engineer of the Year award 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 3Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 4OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2
... to Reveal Successful Strategies for China, India at the PharmAsia... -- SAN FRANCISCO, October 13, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Calif., Oct. 13 Biomerix Corporation ... Patent and Trademark Office (USPTO) has granted ... technology titled "Reticulated elastomeric matrices, their manufacture ... platform technology, the Biomerix Biomaterial™ is a ...
... RICHLAND, Washington A redesign of sodium-nickel chloride batteries ... with rechargeable batteries. Replacing their typical cylindrical shape with ... 30 percent more power at lower temperatures, according to ... October 8 issue of ECS Transactions , a ...
Cached Biology Technology:Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 2Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 3Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 4Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 5Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 6Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 7Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 8Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 9Biomerix Granted US Patent for Its Proprietary Biomaterial Platform Technology 2Planar power 2
(Date:7/23/2014)... emulsions are crucial for providing essential fatty acids ... intravenous feeding. There has been concern that soybean-based ... damage due to its composition. Combination lipid emulsions ... oil have been developed to address this concern. ... found that concern may be unwarranted, according to ...
(Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2014. ... million, an increase of 53% compared to $4.4 million in ... income in the second quarter of 2014 was $1.4 million ... The increase in revenue and operating income was driven by ...
(Date:7/22/2014)... scientific discovery showed that mutations in prickle genes ... disorder characterized by repeated seizures over time. However, ... unknown. , A new University of Iowa study, ... of the National Academy of Sciences , reveals ... UI researchers have identified the basic cellular mechanism ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7UI study finds potential genetic link between epilepsy and neurodegenerative disorders 2
... This release is available in German . ... the numerous biological functions of an organism are not regulated ... mechanisms exist that contribute to determining the fate of genes. ... even be passed on to subsequent generations to a certain ...
... University engineers have taken a first step toward a ... with heat administered from the end of a catheter. ... technically possible to treat brain tumors without the side ... chemotherapy or radiation. The bioengineers designed and built ...
... N.C. In 2004, researchers at the University of ... announced a crucial discovery in the understanding of cellular ... age, the expression of a key protein, called p16INK4a, ... is a tumor suppressor protein, cancer researchers are interested ...
Cached Biology News:New piece found in the puzzle of epigenetics 2Potential for non-invasive brain tumor treatment 2Test detects molecular marker of aging in humans 2
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
... Signet Level 2 Detection System combines ... chemical bonding principle and Signets unique ... sensitivity, specificity and reliablility. Signet reagents ... both manual and automated protocols. ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Biology Products: